Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study

NCT07168291 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT07168291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07168291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Patients With Relapsed or Refractory B-cell Lymphoma: An Open-label, Single-arm Clinical Study
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
December 31, 2028
Enrollment
3 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, diffuse large b cell lymphoma (dlbcl), follicular lymphoma ( fl)